These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1122 related articles for article (PubMed ID: 34791293)

  • 21. An Update on Herbal Products for the Management of Inflammatory Bowel Disease.
    Arya H; Dass R; Chopra B; Kriplani P; Deswal G; Singh Grewal A; Dhingra AK; Kumar S
    Antiinflamm Antiallergy Agents Med Chem; 2023; 22(1):1-9. PubMed ID: 37497699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NLRP3 Inhibitors as Potential Therapeutic Agents for Treatment of Inflammatory Bowel Disease.
    Perera AP; Kunde D; Eri R
    Curr Pharm Des; 2017; 23(16):2321-2327. PubMed ID: 28155620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in biologic therapy for ulcerative colitis and Crohn's disease.
    D'Haens G; Daperno M
    Curr Gastroenterol Rep; 2006 Dec; 8(6):506-12. PubMed ID: 17105690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Research-Based Product Innovation to Address Critical Unmet Needs of Patients with Inflammatory Bowel Diseases.
    Honig G; Larkin PB; Heller C; Hurtado-Lorenzo A
    Inflamm Bowel Dis; 2021 Nov; 27(Suppl 2):S1-S16. PubMed ID: 34791292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor necrosis factor blockade for treatment of inflammatory bowel disease: efficacy and safety.
    Ngo B; Farrell CP; Barr M; Wolov K; Bailey R; Mullin JM; Thornton JJ
    Curr Mol Pharmacol; 2010 Nov; 3(3):145-52. PubMed ID: 20799925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More.
    Misselwitz B; Juillerat P; Sulz MC; Siegmund B; Brand S;
    Digestion; 2020; 101 Suppl 1():69-82. PubMed ID: 32570252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Saffron as a Promising Therapy for Inflammatory Bowel Disease.
    Rashid M; Rashid R; Saroya S; Deverapalli M; Brim H; Ashktorab H
    Nutrients; 2024 Jul; 16(14):. PubMed ID: 39064796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in inflammatory bowel diseases in children.
    Michail S; Ramsy M; Soliman E
    Minerva Pediatr; 2012 Jun; 64(3):257-70. PubMed ID: 22555319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis?
    Danese S; Angelucci E
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S217-27. PubMed ID: 20117345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases.
    Sobczak M; Fabisiak A; Murawska N; Wesołowska E; Wierzbicka P; Wlazłowski M; Wójcikowska M; Zatorski H; Zwolińska M; Fichna J
    Pharmacol Rep; 2014 Oct; 66(5):766-75. PubMed ID: 25149979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.
    Pedersen G
    Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of integrin antagonists in the treatment of inflammatory bowel disease.
    Beniwal-Patel P; Saha S
    Expert Opin Biol Ther; 2014 Dec; 14(12):1815-23. PubMed ID: 25288228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
    Aardoom MA; Veereman G; de Ridder L
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of inflammatory bowel disease (IBD).
    Pithadia AB; Jain S
    Pharmacol Rep; 2011; 63(3):629-42. PubMed ID: 21857074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucocorticoid resistance in inflammatory bowel disease.
    Farrell RJ; Kelleher D
    J Endocrinol; 2003 Sep; 178(3):339-46. PubMed ID: 12967327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current therapy of inflammatory bowel disease in children.
    Rufo PA; Bousvaros A
    Paediatr Drugs; 2006; 8(5):279-302. PubMed ID: 17037946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Crohn's targeted therapy: myth or real goal?
    Schmidt KJ; Büning J; Jankowiak C; Lehnert H; Fellermann K
    Curr Drug Discov Technol; 2009 Dec; 6(4):290-8. PubMed ID: 20025597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review article: novel oral-targeted therapies in inflammatory bowel disease.
    White JR; Phillips F; Monaghan T; Fateen W; Samuel S; Ghosh S; Moran GW
    Aliment Pharmacol Ther; 2018 Jun; 47(12):1610-1622. PubMed ID: 29672874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.